Remove Biopharma Remove FDA Remove Healthcare Remove Side effects
article thumbnail

Regulators and HTAs tune in to patient preference data

Clarivate

Obtaining the preferences of patients and their caregivers is not a new concept in healthcare. Increasingly, however, industry guidance documents utilize the term ‘patient preference’ in relation to new drug development and benefit-risk assessment.

article thumbnail

Drug repurposing, real world data and AI/ML: perspectives and opportunities

Clarivate

Drug candidates have a high rate of failure, as only 10% of de-novo drugs put through clinical trials finally obtain market approval, with the highest rate of attrition occurring at phase I and II of clinical trials (assessing safety, tolerability, dosage, efficacy, and side effects). For example, in the U.S.,

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

How to Work with Patient Advocates, Influencers, and Ambassadors

PM360

Only 5% of patients ranked pharma companies as the most trusted player in the healthcare space, according to a 2021 survey of 500 patients from Accenture. For example, everyone must be steeped in both FDA and FTC guidelines. Once you choose a patient partner, transparency is tantamount to building a successful working relationship.

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. This has been demonstrated recently with PLUVICTO ® , which was the first US Food and Drug Administration (FDA)-approved targeted radioligand therapy for eligible patients with prostate cancer.

article thumbnail

The State of the Union in Cancer Innovation

PM360

The FDA has granted Fast Track Designation for our HER2-targeted ADC, ARX788, and we are enrolling the signal-seeking ACE-Breast-03 Phase 2 clinical study in post-Enhertu mBC patients throughout 2H 2023. Not only can we design drugs better, but we can understand their effects better to engineer small molecules in a more efficient way.

article thumbnail

Exclusive Look at HandX Robotic-Assisted Surgical Device from Human Xtensions

Medgadget

Interestingly, due to FDA’s regulatory methodology, surgical robots have to be approved for specific indications by the agency. ” An attractive proposition in a world in which technology has contributed significantly to the distancing of physicians from their patients, usually leading to negative side effects.